Phase II Trial of Veliparib in Patients with Previously-Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma

PURPOSE: BRCA-associated cancers have increased sensitivity to PARP inhibitors (PARPi). This single arm, non-randomized, multicenter phase II trial evaluated the response rate of velparib in patients with previously-treated BRCA1/2 or PALB2 mutant pancreatic adenocarcinoma (PDAC). METHODS: Patients...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur J Cancer
Glavni autori: Lowery, Maeve A., Kelsen, David P., Capanu, Marinela, Smith, Sloane C., Lee, Jonathan W., Stadler, Zsofia K, Moore, Malcolm J, Kindler, Hedy L., Golan, Talia, Segal, Amiel, Maynard, Hannah, Hollywood, Ellen, Moynahan, MaryEllen, Salo-Mullen, Erin E., Kinh Gian Do, Richard, Chen, Alice P., Yu, Kenneth H., Tang, Laura H., O’Reilly, Eileen M.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7351022/
https://ncbi.nlm.nih.gov/pubmed/29223478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2017.11.004
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items